Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study

Table 4

Logistic regression analysis for the association between the occurrence of adverse event during allogeneic UCBSCs treatment and several predicting factors.

Predicting factors	Significance	Odds ratio	95% confidence interval
			Lower bound	Upper bound
Sex
Female	0.124	4.420	0.664	29.417
Male	—	—	—	—
Birth method
Cesarean	0.381	0.500	0.106	2.362
Natural birth	—	—	—	—
Birth weight
Low birth weight	0.503	0.523	0.078	3.484
Normal birth weight	—	—	—	—
Gestational age
Preterm	0.145	4.494	0.595	33.961
Full term	—	—	—	—
Neonatal jaundice
Yes	0.796	1.287	0.191	8.669
No	—	—	—	—
NHIE
Yes	0.599	0.681	0.163	2.847
No	—	—	—	—
Epilepsy
Yes	0.627	1.456	0.320	6.623
No	—	—	—	—
MIDP
Yes	0.605	1.514	0.314	7.289
No	—	—	—	—
Age at treatment initiation
≤10 years old	0.036	12.543	1.178	133.549
>10 years old	—	—	—	—

Note. UCBSCs: umbilical cord blood stem cells; NHIE: neonatal hypoxic ischemic encephalopathy; MIDP: mother infected during pregnancy.